Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Immunogen Inc

<< Previous

Bullboard Posts

Next >>

Comment by venture009on Nov 30, 2023 10:13pm

145 Views

Post# 35762655

RE:RE:RE:Immunogen Inc

Noteable, like too many of ONC trials the patient population is too small for statisical significanse. If they had 40+ patients in their trial with the same results, I believe we would be getting more recognition. I also wonder if this may be causing some hesitancy in a BP coming forward with an offer.

<< Previous

Bullboard Posts

Next >>

These cold weather stocks are looking to heat up for winter